Patent Assignment
Reel/Frame 023569/0120
Change of Name
Recorded: 2009-11-25
Pages: 26
Assignor
LABORATOIRES SERONO SA
Executed: 2008-12-12
Assignee
MERCK SERONO SA
CENTRE INDUSTRIEL, COINSINS, VAUD, 1267, SWITZERLAND
Covered Properties
(99)
Site-Directed Mutagenesis Modified Glycoprotein Hormones
Patent:
5,260,421 →
Application:
07/136,236 →
Novel Method of Ovulation Induction in Humans
Patent:
5,087,615 →
Application:
07/324,949 →
Ovulation Kit Comprising Fsh Isoforms with Varying Half-Lives
Patent:
5,262,518 →
Application:
07/751,016 →
Method for the Modification of the Expression Characteristics of an Endogenous Gene of a Given Cell Line
Patent:
5,272,071 →
Application:
07/893,447 →
Method and Apparatus for Growing Biomass Particles
Patent:
5,654,197 →
Application:
08/102,098 →
Site-Directed Mutagenesis Modified Dna Encoding Glycoprotein Hormones and Methods of Use
Patent:
5,352,779 →
Application:
08/126,134 →
Gonadotropin Containing Pharmaceutical Compositions with Sucrose Stabilizer
Patent:
5,650,390 →
Application:
08/244,575 →
Site-Directed Mutagenesis Modified Glycoprotein Hormones and Methods of Use
Patent:
5,986,068 →
Application:
08/281,123 →
Human Fc Gamma Receptor Iii
Patent:
5,976,831 →
Application:
08/417,488 →
CD16-Ii Variants
Patent:
6,444,789 →
Application:
08/433,123 →
Site-Directed Mutagenesis Modified Glycoprotein Hormones and Methods of Use
Patent:
5,635,475 →
Application:
08/442,645 →
Site-Directed Mutagenesis Modified Glycoprotein Hormones and Methods of Use
Patent:
5,705,479 →
Application:
08/442,963 →
Methods for Assaying Human Fsh Using Human Fsh Receptor
Patent:
6,372,711 →
Application:
08/474,986 →
Human Fc-Gamma Receptor Iii
Patent:
5,767,077 →
Application:
08/481,939 →
Dna Encoding Human Follicle Stimulating Hormone Receptor,Vectors and Cells Containing Suchdna,and Methods of Use Thereof
Patent:
6,121,016 →
Application:
08/482,855 →
Human Follicle Stimulating Hormone Receptor
Patent:
5,744,448 →
Application:
08/487,886 →
CD16-Ii Variants
Patent:
5,998,166 →
Application:
08/667,939 →
Soluble Polypeptide Fractions of the Lag-3 Protein; Production Method, Therapeutic Composition, Anti-Idiotype Antibodies
Patent:
5,955,300 →
Application:
08/737,271 →
Hybrid Proteins
Patent:
6,193,972 →
Application:
08/804,166 →
Soluble Human Prolactin Receptors
Patent:
6,083,714 →
Application:
08/806,597 →
Hybrid Proteins
Patent:
6,194,177 →
Application:
08/910,991 →
Il-6 Activity Inhibitor
Patent:
6,004,813 →
Application:
08/945,726 →
Soluble Human Prolactin Receptors
Patent:
6,083,753 →
Application:
08/970,428 →
Methods for Detecting, Identifying, Isolating, and Selectively Labelling and Targeting TH1 Lymphocyte by Means of the Lag-3 Protein
Patent:
6,197,524 →
Application:
08/983,576 →
Soluble Polypeptide Fractions of the Lag-3 Protein; Production Method, Therapeutic Composition, Anti-Idiotype Antibodies
Patent:
6,143,273 →
Application:
09/058,555 →
Disulfide Crosslinked Glycoprotein Hormone Analogs, and Their Preparation and Use
Patent:
8,530,190 →
Application:
09/104,400 →
Il-6 Mutein
Patent:
6,280,975 →
Application:
09/155,941 →
IFNAR2/Ifn Complex
Patent:
6,372,207 →
Application:
09/215,212 →
Human Fcy Receptor Iii
Patent:
6,294,347 →
Application:
09/232,218 →
Hcg and Derivatives as Matrix Metalloproteases Inhibitors
Intracellular Glucocorticoid-Induced Leucine Zippers Modulators of Apoptic Cell Death Pathways
Patent:
6,833,348 →
Application:
09/403,861 →
Human Growth Hormone to Stimulate Hematopoiesis and Immune Reconstitution After Hematopoietic Stem Cell Transplantation in Humans
Patent:
6,348,444 →
Application:
09/465,461 →
Treatment of Hiv-Associated Dysmorphia/Dysmetabolic Syndrome (Hadds) with or Without Lipodystrophy
Patent:
6,696,063 →
Application:
09/475,989 →
Use of Mhc Class Ii Ligands as Adjuvant for Vaccination and of Lag-3 in Cancer Treatment
Patent:
6,410,509 →
Application:
09/492,113 →
Amino-Terminally Truncated Rantes as Chemokine Antagonists
Amino-Terminally Truncated Mcp-2 as Chemokine Antagonists
Site-Specific Preparation of Polyethylene Glycol-Grf Conjugates
Patent:
6,528,485 →
Application:
09/587,460 →
Polyol-Ifn-Beta Conjugates Modified at Cys-17 and Composition Containing Same
Patent:
6,638,500 →
Application:
09/698,133 →
Il-6 Antagonist Peptides
Patent:
6,599,875 →
Application:
09/715,923 →
Compound B as Angiogenic Agent in Combination with Human Growth Factors
Hybrid Heterodimeric Protein Comprising a Tnf Binding Protein and a Glycoprotein Hormone Subunit, and Method of Using Same
Chemokine Receptor Antagonist and Cyclosporin in Combined Therapy
Patent:
6,902,728 →
Application:
09/787,335 →
Tumor Necrosis Factor Antagonists and Their Use in Endometriosis
Patent:
6,663,865 →
Application:
09/889,828 →
Soluble Polypeptide Fractions of the LAG03 Protein, Production
Patent:
38,313 →
Application:
09/931,103 →
Gonadotrophins in the Treatment Anovulatory Women
Patent:
7,695,721 →
Application:
09/959,799 →
IL6RIL6 Chimera for the Treatment of Neurodegenerative Diseases
Patent:
7,201,896 →
Application:
09/980,823 →
Pharmaceutically Active Sulfonamide Derivatives
Patent:
8,012,995 →
Application:
10/070,954 →
Benzazole Derivatives and Their Use as Jnk Modulators
Use of Fsh for Treating Infertility
Purified Lh
Process of Purification of Hcg and Recombinant Hcg Purified by That Method
Monoclonal Antibodies to the Human Ldl Receptor, Their Production and Use
Pharmaceutically Active Pyrrolidine Derivatives
Pharmaceutically Active Pyrrolidine Derivatives as Bax Inhibitors
Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
Application:
10/297,755 →
Publication:
US 2004/0028649
Site-Specific Preparation of Polyethlene Glycol-Grf Conjugates
Early Diagnosis of Conformational Diseases
Mehtod of Producing Functional Protein Domains
Il-6 Antagonist Peptides
Chemokine Mutants in the Treatment of Multiple Sclerosis
Use of Sarp-1 for the Treatment and/or Prevention of Scleroderma
Use of Osteopontin for the Treatment and/or Prevention of Neurologic Diseases
Method and Kit for Identifying and/or Quantifying Radiolabeled Aminoglycoside Binding Molecules
Use of Lh in Controlled Ovarian Hyperstimulation
Use of Hcg in Controlled Ovarian Hyperstimulation
Method for Aiding Implantation or Decreasing Miscarriage Rate
Use of GP130 Activators in Diabetic Neuropathy
Mutant Glycoproteins
Gonadotrophins for folliculogenesis
Application:
10/493,638 →
Publication:
US 2005/0085412
Benzazole Derivatives for the Treatment of Scleroderma
Benzothiazole derivatives for the treatment of diabetes
Application:
10/571,291 →
Publication:
US 2007/0088017
Use of Il-6 in Liver Injury
Intracellular Modulators of Apoptopic Cell Death Pathways
Improved Method for Treating Disorders and Diseases Treatable with Human Fibroblast Interferon
Tumor necrosis factor antagonists and their use in endometriosis
Application:
10/666,335 →
Publication:
US 2004/0057954
Improvement of Homogeneity and Secretion of a Recombinant Follicle Stimulating Hormone (Fsh) in Mammalian Systems
Treatment of Hiv-Associated Dysmorphia/Dysmetabolic Syndrome (Hadds) with or Without Lipodystrophy
Homogeneity and Secretion of Recombinant Proteins in Mammalian Systems
Luteinizing Hormone and Follicle Stimulating Hormone for Use in Inducing Folliculogenesis
Use of Osteopontin for the Treatment and/or Prevention of Neurologic Diseases
Compound B as an Angiogenic Agent in Combination with Human Growth Factors
Site-Specific Preparation of Polyethylence Glycol-Grf Conjugates
Use of Amino-Terminally Truncated Rantes to Inhibit Hiv Viral Replication
Amino-Terminally Truncated Mcp-2 as Chemokine Antagonists
Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
Application:
11/237,876 →
Publication:
US 2006/0029581
Purified LH
Application:
11/287,341 →
Publication:
US 2006/0079460
Treatment of Hiv-Associated Dysmorphia/Dysmetabolic Syndrome (Hadds) with or Without Lipodystrophy
Application:
11/552,753 →
Publication:
US 2008/0004217
Compositions and Methods for Therapy or Prevention of Chemotherapy-Induced Neuropathy
Method for Inhibiting a Microvascular Complication by Administering Il-6
A Method for Producing Polyol-Ifn-Beta Conjugate
Use of Osteopontin for the Treatment and/or Prevention of Neurologic Diseases
Application:
11/679,735 →
Publication:
US 2007/0225214
Production of Proteins
Application:
11/720,476 →
Publication:
US 2009/0298055
Method of Inhibiting the Expression and/or the Activity of Jnk
Pharmaceutically active pyrrolidine derivatives
Application:
11/783,341 →
Publication:
US 2008/0167318
DNA coding for polypeptide fusion
Application:
11/861,835 →
Publication:
US 2010/0075402
Polypeptide fusion
Application:
11/929,292 →
Publication:
US 2009/0240039
Use of Osteopontin for the Treatment and/or Prevention of Neurologic Diseases
Application:
11/936,623 →
Publication:
US 2008/0213234
Method for Treating Liver Cirrhosis or Interstitial Pulmonary Fibrosis
USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
Application:
12/336,161 →
Publication:
US 2009/0169506
Related Assignments
(23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignors Interest.
Dec 21, 1987
From: CHAPPEL, SCOTT C.; BERNSTINE, EDWARD G.
To: INTEGRATED GENETICS, INC., FRAMINGHAM
Reel/Frame 004806/0323 →
Assignment of Assignors Interest.
Mar 17, 1989
From: CHAPPEL, SCOTT C.
To: INTEGRATED GENETICS, INC., ONE MOUNTAIN RD., FRAMINGHAM, MA
Reel/Frame 005036/0454 →
Assignment of Assignors Interest.
Sep 1, 1989
From: INTEGRATED GENETICS, INC.
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., JOHN B. GORSIRAWEG
Reel/Frame 005138/0773 →
Assignment of Assignors Interest.
Mar 30, 1990
From: INTEGRATED GENETICS, INC.
To: GENZYME CORPORATION, 75 KNEELAND STREET, BOSTON, MA 02111 A DE CORP.
Reel/Frame 005264/0722 →
Assignment of Assignors Interest.
Mar 30, 1990
From: INTEGRATED GENETICS, INC.
To: GENZYME CORPORATION, 75 KNEELAND STREET, BOSTON, MA 02111 A DE CORP.
Reel/Frame 005264/0732 →
Assignor Hereby Confirms That the Assignee Recorded at Reel 5264 Frame 0722 Was in Error and the Assignment Recorded at Reel 5138 Frame 0773 Recites the Correct Assignee.
Oct 16, 1991
From: GENZYME CORPORATION
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 005870/0987 →
Assignment of Assignor's Interest
Jun 10, 1993
From: CHAPPEL, SCOTT C.
To: APPLIED RESEARCH SYSTEMS
Reel/Frame 006581/0638 →
Assignment of Assignor's Interest
Dec 3, 1993
From: JEM, KWAN-MIN; CEVEY, PIERRE FRANCOIS
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 006794/0312 →
Assignment of Assignor's Interest
Sep 7, 1994
From: SAMARITANI, FABRIZIO; NATALE, PATRIZIA
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 007112/0125 →
Assignment of Assignor's Interest
Oct 23, 1995
From: LUO, SHUN
To: APPLIED RESEARCH SYSTEM ARS HOLDING N.V.
Reel/Frame 007672/0791 →
Assignment of Assignor's Interest
Mar 21, 1997
From: SCHERING CORPORATION
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 008411/0080 →
Assignment of Assignor's Interest
Mar 26, 1997
From: FAURE, FLORENCE; HERCEND, THIERRY; HUARD, BERTRAND; TRIEBEL, FREDERIC
To: INSTITUT GUSTAVE ROUSSY; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 008416/0695 →
Assignment of Assignor's Interest
Aug 26, 1997
From: KELLY, PAUL A.; NAGANO, MAKOTO
To: INSERM; APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 008690/0674 →
Assignment of Assignor's Interest
Sep 22, 1997
From: CAMPBELL, ROBERT; JAMESON, BRADFORD A.; CHAPPEL, SCOTT C.
To: APPLIED RESEARCH SYSTEMS ARS HOLDING NV
Reel/Frame 008717/0790 →
Assignment of Assignor's Interest
Dec 18, 1997
From: CAMPBELL, ROBERT K.; JAMESON, BRADFORD A.; CHAPPEL, SCOTT C.
To: APPLIED RESEARCH SYSTEMS ARS HOLDING NV
Reel/Frame 008863/0796 →
Assignment of Assignor's Interest
Mar 13, 1998
From: SERLUPI-CRESCENZI, OTTAVIANO; PEZZOTTI, ANNARITA
To: APPLIED RESEARCH SYSTEMS ARS HOLDING
Reel/Frame 009041/0719 →
Assignment of Assignor's Interest
May 21, 1998
From: ROMAGNANI, SERGIO
To: INSTITUT GUSTAVE ROUSSY
Reel/Frame 009183/0489 →
Assignment of Assignor's Interest
May 3, 1999
From: ROMAGNANI, SERGIO
To: INSTITUTE GUSTAVE ROUSSY; INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 009927/0624 →
Change of Address
May 19, 2000
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 010804/0904 →
Change of Address
Oct 27, 2000
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 011245/0159 →
Assignment of Assignor's Interest
Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →
Assignment of Assignor's Interest
Oct 10, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019938/0234 →
Corrective Assignment to Correct the Incorrect Serial Numbers 07/244,575 and 08/074,465 Previously Recorded on Reel 019966 Frame 0026. Assignor(S) Hereby Confirms the Assignment of Entire Interest.
Apr 23, 2009
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 022587/0160 →